Cite
HARVARD Citation
Schadendorf, D. et al. (2017). Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. European journal of cancer. pp. 45-55. [Online].